Table 1.
Patient characteristics.
| Number of Patients (%) (Total Number of Patients n = 73) |
|
|---|---|
| Sex | |
| Male | 42 (58) |
| Female | 31 (42) |
| Median age at diagnosis (years) | 63 (range 36–80) |
| Binet stage initial diagnosis | |
| A | 48 (66) |
| B | 15 (21) |
| C | 6 (8) |
| not available | 4 (5) |
| Rai stage initial diagnosis | |
| 0 | 20 (27) |
| I–II | 32 (44) |
| III–IV | 6 (8) |
| not available | 15 (21) |
| Binet stage sample acquisition | |
| A | 32 (44) |
| B | 22 (30) |
| C | 17 (23) |
| not available | 2 (3) |
| Rai stage sample acquisition | |
| 0 | 12 (16) |
| I–II | 38 (53) |
| III–IV | 21 (28) |
| not available | 2 (3) |
| IGHV mutational status | |
| mutated | 10 (59) |
| unmutated | 7 (41) |
| CD38 expression | |
| <20% | 43 (59) |
| 20–29% | 3 (4) |
| ≥30% | 15 (21) |
| not available | 12 (16) |
| Cytogenetics risk | |
| favorable * | 5 (7) |
| intermediate * | 4 (5) |
| poor * | 10 (14) |
| not available | 54 (74) |
| TP53 mutation | |
| Positive | 3 (4) |
| negative | 20 (27) |
| not available | 50 (68) |
| Lymphocyte count (1/µL) | 43,984 (range 5366–320,330) |
| Hb (g/dL) | 12.7 (range 7.9–16.8) |
| Plt (1000/µL) | 183 (range 14–346) |
| β-2 microglobuline (mg/L) | 3.7 (range 1.7–9.7) |
Hb: haemoglobin; plt: thrombocytes; * classical cytogenetic analyses were performed, and patient grouped accordingly: favorable: 12q trisomy, del 13q; intermediate: normal karyotype; poor: del17p, del11q.